<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03038451</url>
  </required_header>
  <id_info>
    <org_study_id>NEU-07.12</org_study_id>
    <nct_id>NCT03038451</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients</brief_title>
  <official_title>Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients: Open-label, Local, Phase IV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neutec Ar-Ge San ve Tic A.Ş</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neutec Ar-Ge San ve Tic A.Ş</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      s-amlodipine besylate 2,5 mg tablet will be administered to patients have not received any
      hypertension treatment before or have received any of anti-hypertensive mono-therapy for the
      first four weeks of treatment. By increasing dose, s-amlodipine besylate 5 mg tablet will be
      administered for the last four weeks (4-8 weeks).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2013</start_date>
  <completion_date type="Actual">February 14, 2017</completion_date>
  <primary_completion_date type="Actual">February 14, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of change in systolic blood pressure up to 4th week of the treatment</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of change in diastolic blood pressure up to 4th week of the treatment</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of change in diastolic blood pressure up to 8th week of the treatment</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of change in systolic blood pressure up to 8th week of the treatment</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of change in systolic blood pressure from 4th to 8th week of the treatment</measure>
    <time_frame>4 to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of change in diastolic blood pressure from 4th to 8th week of the treatment</measure>
    <time_frame>4 to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of treatment response rates from 4th to 8th week of the treatment</measure>
    <time_frame>4 to 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>s-amlodipine besylate 2,5 and 5 mg tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-NOR (s-amlodipine) 2,5 mg &amp; 5 mg tablet</intervention_name>
    <arm_group_label>s-amlodipine besylate 2,5 and 5 mg tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients 18 years and older.

          -  Hypertension patients have not received any anti-hypertensive treatment before ( ≥ 140
             mmHg MSSBP &lt; 160 mmHg, ≥ 90 mmHg MSDBP &lt; 100mmHg).

          -  Hypertension patients controlled with single medicine.

          -  Patients giving written informed consent without being under any influence.

        Exclusion Criteria:

          -  Pregnant patients, nursing mothers or female patients who have potential for
             childbearing and do not use any effective contraceptive method.

          -  Allergy or hypersensitivity to dihydropyridines.

          -  Patients receive more than one anti-hypertensive medicine.

          -  Patients with seconder hypertension.

          -  Patients with severe hypertension, myocardial infarction, NYHA stage 2-4 cardiac
             insufficiency, history of cerebrovascular disease, past ischemic attack,
             encephalopathy, underwent coronary artery bypass surgery or percutaneous coronary
             intervention, second or third degree heart block or symptomatic arrhythmia without
             pacemaker, clinically significant heart valve disease, potential life-threatening or
             symptomatic arrhythmia, simultaneous unstable angina pectoris, type I diabetes
             mellitus, atrial fibrillation until the last 12 months.

          -  Uncontrolled type II diabetes mellitus.

          -  Patients with significant liver disease (ALT, AST must be &gt; 2XULN in beginning,
             patients with esophageal varices, portacaval shunt).

          -  Patients with significant kidney disease (GFR &lt;60 ml/min according to Cockcroft-Gault
             formula).

          -  Patients with volume depletion.

          -  Patients with pancreas disease.

          -  Patients with gastrointestinal disease which may effect absorption.

          -  Drug/narcotic and alcohol abuse until the last 12 months.

          -  Patients with central nervous system disease and taking medicine for this reason.

          -  History of incompatibility with medical regimes or patients do not want to adhere the
             study protocol.

          -  Persons directly involved in the management of this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Istanbul University Istanbul Medical Faculty Clinical Pharmacology Department</name>
      <address>
        <city>Istanbul</city>
        <state>Fatih</state>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2017</study_first_submitted>
  <study_first_submitted_qc>January 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

